Clinical pharmacology of coronary thrombolysis.
Pharmacologic thrombolysis is dependent on activation of endogenous plasminogen to the active proteolytic enzyme, plasmin. Agents such as tissue-plasminogen activator with a high affinity for fibrin bound plasminogen result in high local concentration of plasmin. Thus, they achieve clot lysis with less tendency to induce a systemic lytic state reflecting extensive fibrinogenolytic activity in the circulation. Appropriate dose regimens for thrombolytic agents in specific clinical situations is critical to maximize therapeutic efficacy while minimizing the risk of significant bleeding.
D003327:Coronary Disease / Q000188:drug therapy*; D003328:Coronary Thrombosis / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D013300:Streptokinase / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator